FIL Ltd decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,436 shares of the medical instruments supplier’s stock after selling 374 shares during the period. FIL Ltd’s holdings in Becton, Dickinson and were worth $14,133,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. MML Investors Services LLC boosted its position in Becton, Dickinson and by 11.3% during the second quarter. MML Investors Services LLC now owns 5,272 shares of the medical instruments supplier’s stock valued at $1,029,000 after purchasing an additional 536 shares during the last quarter. TIAA FSB acquired a new stake in Becton, Dickinson and during the second quarter valued at $7,373,000. ETRADE Capital Management LLC boosted its position in Becton, Dickinson and by 19.6% during the second quarter. ETRADE Capital Management LLC now owns 14,889 shares of the medical instruments supplier’s stock valued at $2,905,000 after purchasing an additional 2,437 shares during the last quarter. Quantum Capital Management boosted its position in Becton, Dickinson and by 7.3% during the second quarter. Quantum Capital Management now owns 1,499 shares of the medical instruments supplier’s stock valued at $292,000 after purchasing an additional 102 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Becton, Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares during the last quarter. 87.12% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Stephen Sichak sold 11,787 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the sale, the insider now directly owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the sale, the insider now directly owns 12,861 shares in the company, valued at $2,538,890.01. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by insiders.

Becton, Dickinson and Company (NYSE BDX) opened at 200.82 on Tuesday. The stock has a 50 day moving average price of $197.13 and a 200-day moving average price of $193.13. The company has a market capitalization of $45.70 billion, a price-to-earnings ratio of 58.16 and a beta of 1.05. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.35 EPS. Equities analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were issued a $0.73 dividend. The ex-dividend date of this dividend was Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.45%. Becton, Dickinson and’s payout ratio is 83.43%.

ILLEGAL ACTIVITY WARNING: “FIL Ltd Trims Position in Becton, Dickinson and Company (BDX)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/17/fil-ltd-trims-position-in-becton-dickinson-and-company-bdx.html.

A number of research firms recently issued reports on BDX. Barclays PLC reissued an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $200.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.